Search research articles
Contact Us
Filters
Showing results (81-90 of 91) with videos related to
Page
of 10
Sort By:
Bioorganic & Medicinal Chemistry Letters
|
March 1, 2006
Design of a potent, soluble glucokinase activator with excellent in vivo efficacy
Darren McKerrecher, Joanne V Allen, Peter W R Caulkett, et al.
Bioorganic & Medicinal Chemistry Letters
|
April 26, 2011
Design of a potent, soluble glucokinase activator with increased pharmacokinetic half-life
Kurt G Pike, Joanne V Allen, Peter W R Caulkett, et al.
The Journal of Physiology
|
September 11, 2024
Acute exercise alters brain glucose metabolism in aging and Alzheimer's disease
Zachary D Green, Casey S John, Paul J Kueck, et al.
Analytical Biochemistry
|
November 23, 2006
Binding thermodynamics of substituted diaminopyrimidine renin inhibitors
Ronald W Sarver, Jeanette Peevers, Wayne L Cody, et al.
Journal of Medicinal Chemistry
|
July 26, 2002
Discovery and optimization of a series of carbazole ureas as NPY5 antagonists for the treatment of obesity
Michael H Block, Scott Boyer, Wayne Brailsford, et al.
Cancer Research
|
March 30, 2016
AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models
Hazel M Weir, Robert H Bradbury, Mandy Lawson, et al.
Journal of Medicinal Chemistry
|
September 26, 2015
Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist
Chris De Savi, Robert H Bradbury, Alfred A Rabow, et al.
Bioorganic & Medicinal Chemistry Letters
|
May 22, 2012
Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes
William McCoull, Matthew S Addie, Alan M Birch, et al.
Journal of Medicinal Chemistry
|
December 11, 2020
Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies
Bernard Barlaam, Robert Casella, Justin Cidado, et al.
The Journal of Clinical Investigation
|
December 24, 2024
Targeted degradation of oncogenic KRASG12V triggers antitumor immunity in lung cancer models
Dezhi Li, Ke Geng, Yuan Hao, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 91) with videos related to
Sort By:
Page
of 10
Bioorganic & Medicinal Chemistry Letters
|
March 1, 2006
Design of a potent, soluble glucokinase activator with excellent in vivo efficacy
Darren McKerrecher, Joanne V Allen, Peter W R Caulkett, et al.
Bioorganic & Medicinal Chemistry Letters
|
April 26, 2011
Design of a potent, soluble glucokinase activator with increased pharmacokinetic half-life
Kurt G Pike, Joanne V Allen, Peter W R Caulkett, et al.
The Journal of Physiology
|
September 11, 2024
Acute exercise alters brain glucose metabolism in aging and Alzheimer's disease
Zachary D Green, Casey S John, Paul J Kueck, et al.
Analytical Biochemistry
|
November 23, 2006
Binding thermodynamics of substituted diaminopyrimidine renin inhibitors
Ronald W Sarver, Jeanette Peevers, Wayne L Cody, et al.
Journal of Medicinal Chemistry
|
July 26, 2002
Discovery and optimization of a series of carbazole ureas as NPY5 antagonists for the treatment of obesity
Michael H Block, Scott Boyer, Wayne Brailsford, et al.
Cancer Research
|
March 30, 2016
AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models
Hazel M Weir, Robert H Bradbury, Mandy Lawson, et al.
Journal of Medicinal Chemistry
|
September 26, 2015
Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist
Chris De Savi, Robert H Bradbury, Alfred A Rabow, et al.
Bioorganic & Medicinal Chemistry Letters
|
May 22, 2012
Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes
William McCoull, Matthew S Addie, Alan M Birch, et al.
Journal of Medicinal Chemistry
|
December 11, 2020
Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies
Bernard Barlaam, Robert Casella, Justin Cidado, et al.
The Journal of Clinical Investigation
|
December 24, 2024
Targeted degradation of oncogenic KRASG12V triggers antitumor immunity in lung cancer models
Dezhi Li, Ke Geng, Yuan Hao, et al.
Page
of 10